![(−)-3,4,4a,5,6,10b-Hexahydro-2H-naphtho[1,2-b][1,4]oxazin-9-ol, HCl - chemical structure image](https://media.scbt.com/product/3-4-4a-5-6-10b-hexahydro-2h-naphtho1-2-b1-4oxazin-9-ol-hcl-structure_26_21_b_262150.jpg)
![(−)-3,4,4a,5,6,10b-Hexahydro-2H-naphtho[1,2-b][1,4]oxazin-9-ol, HCl - chemical structure image](https://media.scbt.com/product/3-4-4a-5-6-10b-hexahydro-2h-naphtho1-2-b1-4oxazin-9-ol-hcl-structure_26_21_t_262150.jpg "Molecular structure of (−)-3,4,4a,5,6,10b-Hexahydro-2H-naphtho[1,2-b][1,4]oxazin-9-ol, HCl")
Molecular structure of (−)-3,4,4a,5,6,10b-Hexahydro-2H-naphtho[1,2-b][1,4]oxazin-9-ol, HCl
(-)-3,4,4a,5,6,10b-Hexahydro-2H-naphtho[1,2-b][1,4]oxazin-9-ol, HCl
Application:
(−)-3,4,4a,5,6,10b-Hexahydro-2H-naphtho[1,2-b][1,4]oxazin-9-ol, HCl is a dopamine receptor antagonist
Molecular Weight:
241.71
Molecular Formula:
C12H16ClNO2
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
A dopamine antagonist. A dopaminergic ligand. This compound has been used as a precursor for the PET radiotracer, 11C-(−)-4-Propyl-3,4,4a,5,6,10b-hexahydro-2H-naphtho[1,2-b][1,4]oxazin-9-ol.
(-)-3,4,4a,5,6,10b-Hexahydro-2H-naphtho[1,2-b][1,4]oxazin-9-ol, HCl References
Dijkstra, D., et al.: J. Med. Chem., 45, 3022 (2002); Wilson, A.A. et al.: J. Med. Chem., 48, 4153 (2005)Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
(-)-3,4,4a,5,6,10b-Hexahydro-2H-naphtho[1,2-b][1,4]oxazin-9-ol, HCl, 5 mg | sc-216586 | 5 mg | $380.00 |